al disease. As a result,
the FDA has recently approved two drug-coated balloon devices for the treatment of occlusive lesions in the SFA and
popliteal artery. It remains unclear how drug coated balloon
angioplasty will compare in durability to other approaches
such as stents referenced above. Bioabsorbable DESs are
currently being evaluated in Europe but are not available
within the United States.
The efÔ¨Åcacy of EVT must also be weighed against the
potential